Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Zeo Energy Corp and its officers or directors [1] Group 1: Company Compliance Issues - On May 29, 2025, Zeo announced it received a notice from Nasdaq regarding non-compliance with periodic filing requirements due to the failure to file its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 by the due date of May 15, 2025 [3] - Following this announcement, Zeo's stock price decreased by $0.34 per share, representing a 9.91% decline, closing at $3.09 per share on May 30, 2025 [3] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Sanofi and its officers or directors [1] Group 1: Company Performance - On May 30, 2025, Sanofi released mixed results from a Phase 3 program for itepekimab, an antibody therapy for chronic obstructive pulmonary disease, with the AERIFY-1 trial meeting its primary endpoint while the AERIFY-2 trial did not [3] - Following the announcement, Sanofi's American Depositary Receipt (ADR) price dropped by $2.98, or 5.69%, closing at $49.37 per ADR on the same day [3] Group 2: Legal Investigation - The investigation by Pomerantz LLP is focused on whether Sanofi and certain officers or directors have engaged in securities fraud or other unlawful business practices [1] - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Arvinas, Inc. and its officers or directors [1] Company Developments - On May 1, 2025, Arvinas announced the removal of plans for a Phase 3 first-line combination trial with atirmociclib and a Phase 3 second-line combination trial with a CDK4/6 inhibitor from its joint development plan with Pfizer [3] - The decision to remove these trials was based on a review of emerging information, external data results, the evolving treatment landscape in metastatic breast cancer, and long-term capital allocation [3] - Arvinas also announced a workforce reduction of approximately one-third to streamline operations and enable efficient progression of its portfolio, with completion planned for the second quarter of 2025 [3] - Following this news, Arvinas's stock price fell by $2.39 per share, or 24.84%, closing at $7.23 per share on May 1, 2025 [3]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Take-Two Interactive Software, Inc. and its officers or directors [1]. Group 1: Company Developments - On May 2, 2025, Take-Two's subsidiary Rockstar Games announced a new release date for Grand Theft Auto VI, moving it to May 26, 2026, from a previously projected fall 2025 release [3]. - Following the announcement of the delayed release, Take-Two's stock price dropped by $15.67 per share, or 6.66%, closing at $219.50 per share on the same day [3]. Group 2: Legal Investigation - Pomerantz LLP is actively seeking investors of Take-Two who may have been affected by the alleged securities fraud and unlawful business practices [1]. - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. and its officers or directors [1] Financial Performance - On May 8, 2025, Globus reported non-GAAP earnings per share of $0.68, missing consensus estimates by $0.06 [3] - The company reported revenue of $598.12 million, which was $27.78 million below consensus estimates and represented a 1.4% year-over-year decline [3] - Following the financial results announcement, Globus's stock price fell by $16.64 per share, or 22.96%, closing at $55.82 per share on May 9, 2025 [3] Company Challenges - The decline in financial performance was attributed to softer Enabling Technology deal closures, temporary integration-related supply chain disruptions, and the timing of international distributor orders [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Travere Therapeutics, Inc. and its officers or directors [1] Group 1: Company Developments - On May 15, 2025, Travere announced that the FDA plans to hold an advisory committee meeting regarding its supplemental New Drug Application for FILSPARI, aimed at treating focal segmental glomerulosclerosis [3] - Following the FDA announcement, Travere's stock price dropped by $4.35 per share, a decline of 20.57%, closing at $16.80 per share on May 16, 2025 [3] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4] - The firm has successfully recovered numerous multimillion-dollar damages awards for class members over its 85-year history [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Savara Inc. and its officers or directors, following a significant stock price drop after negative FDA news [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Savara Inc. and is looking into claims of securities fraud or other unlawful business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1]. Group 2: Stock Performance - On May 27, 2025, Savara announced it received a refusal to file letter from the FDA regarding its Biologics License Application for MOLBREEVI, leading to a stock price decline of $0.90 per share, or 31.69%, closing at $1.94 per share [3].

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit is pending against Rocket Companies, Inc. (“Rocket Companies” or the “Company”) (NYSE: RKT). Investors in Rocket Companies securities are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whet ...

Core Viewpoint - Open Lending Corporation is facing a class action lawsuit due to significant financial losses and misleading statements regarding its business operations and revenue forecasts during the class period from February 24, 2022, to March 31, 2025 [1][5]. Financial Performance - On March 17, 2025, Open Lending announced it would delay its Annual Report for 2024, leading to a share price drop of $0.40, or 9.28%, closing at $3.91 [2]. - The following day, the stock fell further by $0.42, or 10.87%, to close at $3.49 [2]. - On March 31, 2025, the company reported a quarterly revenue of negative $56.9 million, primarily due to an $81.3 million reduction in estimated profit share revenues linked to heightened delinquencies and defaults on loans originated between 2021 and 2024 [3]. - The company also reported a net loss of $144 million, impacted by an $86.1 million valuation allowance on deferred tax assets [3]. Share Price Reaction - Following the financial disclosures on April 1, 2025, Open Lending's share price plummeted by $1.59, or 57.61%, closing at $1.17 [4]. Lawsuit Details - The class action lawsuit alleges that Open Lending made materially false and misleading statements regarding its risk-based pricing models, profit share revenue, and the value of its vintage loans [5]. - Specific allegations include misrepresentation of the capabilities of the company's pricing models and failure to disclose the significant depreciation of its 2021 and 2022 vintage loans [5]. Legal Action - Investors who purchased Open Lending securities during the class period have until June 30, 2025, to file a lead plaintiff motion in the class action lawsuit [1][6].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In DoubleVerify To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in DoubleVerify between November 10, 2023 and February 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 4, 2025 ...